Investor Clive Meanwell on designing biotechs for population health, and AI's role as a catalyst

June 29, 2026 - 08:36

Clive Meanwell, the chairman of Population Health Partners, admits he was a skeptic when it came to artificial intelligence. For a long time, he did not see how the technology could meaningfully shift the needle in drug development or healthcare delivery. But in the last year, his view has flipped. He now describes AI not as a gimmick, but as a genuine catalyst for change.

Meanwell argues that the biotech industry has spent decades designing drugs for narrow patient groups, often ignoring the broader social and economic factors that drive disease. He believes the next wave of successful companies will be those that design interventions with population health in mind, meaning they consider how a treatment fits into real-world systems, from diagnosis to long-term management. AI, in his view, accelerates this shift by making it cheaper and faster to analyze massive datasets, identify hidden patient clusters, and predict which therapies will work outside the controlled environment of a clinical trial.

He points to the falling cost of genomic sequencing and the rise of wearable health data as examples of raw material that AI can finally make sense of. Without AI, he says, researchers drown in information. With it, they can spot patterns that lead to better trial designs and more targeted drugs. Meanwell is careful not to oversell the hype. He notes that AI still struggles with messy, incomplete data and that regulatory frameworks lag behind the technology. But he is convinced that the companies that ignore this shift will be left behind. For him, the real opportunity is not in building a better algorithm, but in using AI to ask smarter questions about why people get sick and how to keep them healthy at scale.